Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review

We report the case of a 73-year-old male with primary myeloid sarcoma (MS) of the prostate. He underwent remission-induction chemotherapy followed by conventional consolidation for acute myeloid leukemia (AML). One year after initial diagnosis, he was without evidence of AML, the longest reported pe...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in hematology 2018-01, Vol.2018 (2018), p.1-5
Main Authors: Nguyen, Ryan, Sayar, Hamid
Format: Article
Language:English
Subjects:
Age
Bone marrow
Cancer
Cancer therapies
Case Report
Case reports
Chemotherapy
Classification
Clinical outcomes
Family medical history
Hematology
Leukemia
Literature reviews
Lymphoma
Medical imaging
NMR
Nuclear magnetic resonance
Oncology
Patients
Prostate
Prostate cancer
Sarcoma
Tomography
Tumors
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the case of a 73-year-old male with primary myeloid sarcoma (MS) of the prostate. He underwent remission-induction chemotherapy followed by conventional consolidation for acute myeloid leukemia (AML). One year after initial diagnosis, he was without evidence of AML, the longest reported period of time in the literature for a case of primary MS of the prostate. From 1985 to 2017, fifteen other cases of MS of the prostate have been reported and are reviewed here. Five cases occurred as primary MS, without evidence of AML on bone marrow examination or prior history of hematologic disorders, and progressed to AML within a range of three weeks to seven months. None of these cases were started on conventional chemotherapy for AML prior to progression. Due to its rarity, primary MS of the prostate is often diagnosed incidentally, but prompt AML-targeted treatment is crucial to delaying the progression to AML.
ISSN:2090-6560
2090-6579
DOI:10.1155/2018/3604298